Literature DB >> 25359584

Emerging roles of regulatory T cells in tumour progression and metastasis.

Elizabeth C Halvorsen1, Sahar M Mahmoud, Kevin L Bennewith.   

Abstract

The metastasis of cancer is a complex and life-threatening process that is only partially understood. Immune suppressive cells are recognized as important contributors to tumour progression and may also promote the development and growth of tumour metastases. Specifically, regulatory T cells (Tregs) have been found to promote primary tumour progression, and emerging pre-clinical data suggests that Tregs may promote metastasis and metastatic tumour growth. While the precise role that Tregs play in metastatic progression is understudied, recent findings have indicated that by suppressing innate and adaptive anti-tumour immunity, Tregs may shield tumour cells from immune detection, and thereby allow tumour cells to survive, proliferate and acquire characteristics that facilitate dissemination. This review will highlight our current understanding of Tregs in metastasis, including an overview of pre-clinical findings and discussion of clinical data regarding Tregs and therapeutic outcome. Evolving strategies to directly ablate Tregs or to inhibit their function will also be discussed. Improving our understanding of how Tregs may influence tumour metastasis may lead to novel treatments for metastatic cancer.

Entities:  

Mesh:

Year:  2014        PMID: 25359584     DOI: 10.1007/s10555-014-9529-x

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  29 in total

Review 1.  Th17 Cells in Helicobacter pylori Infection: a Dichotomy of Help and Harm.

Authors:  Beverly R E A Dixon; Rafat Hossain; Rachna V Patel; Holly M Scott Algood
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

2.  IL-33 increases ST2+ Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent manner.

Authors:  E C Halvorsen; S E Franks; B J Wadsworth; B T Harbourne; R A Cederberg; C A Steer; I Martinez-Gonzalez; J Calder; W W Lockwood; K L Bennewith
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

3.  Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs.

Authors:  E C Halvorsen; M J Hamilton; A Young; B J Wadsworth; N E LePard; H N Lee; N Firmino; J L Collier; K L Bennewith
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 4.  Regulatory T cells in the treatment of disease.

Authors:  Amir Sharabi; Maria G Tsokos; Ying Ding; Thomas R Malek; David Klatzmann; George C Tsokos
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

5.  STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer.

Authors:  Ayman J Oweida; Laurel Darragh; Andy Phan; David Binder; Shilpa Bhatia; Adam Mueller; Benjamin Van Court; Dallin Milner; David Raben; Richard Woessner; Lynn Heasley; Raphael Nemenoff; Eric Clambey; Sana D Karam
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

6.  PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma.

Authors:  Wenliang Pan; Marc Scherlinger; Nobuya Yoshida; Maria G Tsokos; George C Tsokos
Journal:  J Immunol       Date:  2022-07-13       Impact factor: 5.426

7.  Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma.

Authors:  Zhi-Yong Shi; Sheng-Xiao Zhang; Di Fan; Cai-Hong Li; Zhe-Hao Cheng; Yan Xue; Li-Xiang Wu; Ke-Yi Lu; Su-Yun Yang; Yan Cheng; Zhi-Fang Wu; Chong Gao; Xiao-Feng Li; Hai-Yan Liu; Si-Jin Li
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

8.  Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal.

Authors:  Wojciech Jóźwicki; Anna A Brożyna; Jerzy Siekiera; Andrzej T Slominski
Journal:  Oncotarget       Date:  2016-03-08

9.  Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells.

Authors:  Xu Shuai; Li Wei-min; Ya-lin Tong; Ning Dong; Zhi-yong Sheng; Yong-ming Yao
Journal:  Sci Rep       Date:  2015-09-28       Impact factor: 4.379

10.  Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage.

Authors:  Angelica Canossi; Anna Aureli; Tiziana Del Beato; Piero Rossi; Luana Franceschilli; Flavio De Sanctis; Pierpaolo Sileri; Nicola di Lorenzo; Oreste Buonomo; Davide Lauro; Adriano Venditti; Giuseppe Sconocchia
Journal:  J Transl Med       Date:  2016-08-12       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.